Search
BCG-unresponsive non-muscle invasive bladder cancer
go.drugbank.com/conditions/DBCOND0153568Synonyms: Non-muscle invasive bladder cancer ("nmibc") unresponsive/intolerant to bcgCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseTrolamine salicylate
go.drugbank.com/drugs/DB11079ApprovedTrolamine salicylate serves as an active ingredient in topical over-the-counter products for temporary management of mild to moderate muscular and joint pains. … Trolamine salicylate is an organic compound or a salt formed between triethanolamine and salicylic acid. Triethanolamine neutralizes the acidity of the salicylic acid.
Products: Ultracin T, No Odour CreamElafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC). … Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis.
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalIt appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds with 4 or More RingsBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalCompared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … [L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors.
Categories: Antidepressive Agents Indicated for Depression, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeZalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnThis modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. … The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseNarsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigational[A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults
Ritonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalRitonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].[L40094] … Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseDinoprostone
go.drugbank.com/drugs/DB00917ApprovedInvestigationalAs a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour. … It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.